AMRN


Amarin Pops 4% After-Hours On Positive PCI Data For Vascepa

Shares in Amarin (AMRN) popped 4% in Thursday’s after hours trading after the company presented encouraging data on Vascepa (icosapent ethyl) in patients …

Amarin’s Vascepa To Take Part In Covid-19 Study In Adults With Heart Disease

Amarin announced on Friday that Kaiser Permanente Northern California (KPNC) is initiating a trial to study the potential of its lead product Vascepa to …

Amarin, Apotex Settle Vascepa Dispute; Analyst Stays Sidelined

Amarin (AMRN) has announced a settlement agreement with Apotex Inc. that resolves a patent litigation over Apotex’s abbreviated new drug application (ANDA) seeking …

Amarin Down 10% in Pre-Market On Generic Approval

Shares in Amarin (AMRN) are plunging 10% in Friday’s pre-market trading on the news that Hikma Pharmaceuticals (HKMPY) has received approval from the …

Amarin (AMRN) Stock Could Stage a Rebound to $15, Says Analyst

Barely a month ago, investors of Amarin (AMRN) were left dismayed following a lost patent trial against two generic drug makers seeking to …

Amarin (AMRN): All Eyes on Vascepa Appeal Verdict

Investors of Amarin (AMRN), the maker of high triglycerides treatment, Vascepa, have had a rough 2020. Despite a strong rebound in April, the …

Amarin Reports Strong 1Q Vascepa Sales; Plans Patent Appeal For May

Biotech Amarin (AMRN) has announced strong preliminary 1Q20 sales of $150 million for its fish-oil derivative Vascepa, easily beating the consensus estimate of …

Amarin (AMRN) Will Make Excellent Takeover Target, Says Analyst

Every time a door shuts, another window of opportunity opens, the old saying sort of goes. At least that is how one analyst …

Judge’s Record Looks Unpromising for Amarin’s Appeal; Analyst Remains Bullish

It hasn’t been a good week for biotech Amarin (AMRN). On Monday, a District of Nevada judge ruled against the company and in favor of two generic drug makers seeking to establish their own versions of Amarin’s treatment for high triglycerides, Vascepa, …

Judicial Ruling Guts Amarin (AMRN) Stock; What’s Next?

If after seeing Amarin (AMRN) stock tumble 35% over the past year, you consoled yourself with the knowledge that “at least it can’t …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts